318 related articles for article (PubMed ID: 29617661)
1. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
Ge Z; Leighton JS; Wang Y; Peng X; Chen Z; Chen H; Sun Y; Yao F; Li J; Zhang H; Liu J; Shriver CD; Hu H; ; Piwnica-Worms H; Ma L; Liang H
Cell Rep; 2018 Apr; 23(1):213-226.e3. PubMed ID: 29617661
[TBL] [Abstract][Full Text] [Related]
2. Identification of druggable cancer driver genes amplified across TCGA datasets.
Chen Y; McGee J; Chen X; Doman TN; Gong X; Zhang Y; Hamm N; Ma X; Higgs RE; Bhagwat SV; Buchanan S; Peng SB; Staschke KA; Yadav V; Yue Y; Kouros-Mehr H
PLoS One; 2014; 9(5):e98293. PubMed ID: 24874471
[TBL] [Abstract][Full Text] [Related]
3. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
Narayan S; Bader GD; Reimand J
Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Wang Y; Xu X; Maglic D; Dill MT; Mojumdar K; Ng PK; Jeong KJ; Tsang YH; Moreno D; Bhavana VH; Peng X; Ge Z; Chen H; Li J; Chen Z; Zhang H; Han L; Du D; Creighton CJ; Mills GB; ; Camargo F; Liang H
Cell Rep; 2018 Oct; 25(5):1304-1317.e5. PubMed ID: 30380420
[TBL] [Abstract][Full Text] [Related]
5. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
6. Pathway and network analysis of more than 2500 whole cancer genomes.
Reyna MA; Haan D; Paczkowska M; Verbeke LPC; Vazquez M; Kahraman A; Pulido-Tamayo S; Barenboim J; Wadi L; Dhingra P; Shrestha R; Getz G; Lawrence MS; Pedersen JS; Rubin MA; Wheeler DA; Brunak S; Izarzugaza JMG; Khurana E; Marchal K; von Mering C; Sahinalp SC; Valencia A; ; Reimand J; Stuart JM; Raphael BJ;
Nat Commun; 2020 Feb; 11(1):729. PubMed ID: 32024854
[TBL] [Abstract][Full Text] [Related]
7. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis identifies telomerase-associated signatures and cancer subtypes.
Luo Z; Wang W; Li F; Songyang Z; Feng X; Xin C; Dai Z; Xiong Y
Mol Cancer; 2019 Jun; 18(1):106. PubMed ID: 31179925
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of ubiquitin ligases in cancer.
Qi J; Ronai ZA
Drug Resist Updat; 2015 Nov; 23():1-11. PubMed ID: 26690337
[TBL] [Abstract][Full Text] [Related]
10. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data.
Li Y; Kang K; Krahn JM; Croutwater N; Lee K; Umbach DM; Li L
BMC Genomics; 2017 Jul; 18(1):508. PubMed ID: 28673244
[TBL] [Abstract][Full Text] [Related]
12. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
13. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
Mamidi TKK; Wu J; Hicks C
BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
[TBL] [Abstract][Full Text] [Related]
14. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
15. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis.
Sehat B; Andersson S; Girnita L; Larsson O
Cancer Res; 2008 Jul; 68(14):5669-77. PubMed ID: 18632619
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
17. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
[TBL] [Abstract][Full Text] [Related]
18. SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.
Klotz K; Cepeda D; Tan Y; Sun D; Sangfelt O; Spruck C
Exp Cell Res; 2009 Jul; 315(11):1832-9. PubMed ID: 19084516
[TBL] [Abstract][Full Text] [Related]
19. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
Wang M; Yang C; Zhang X; Li X
Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
[TBL] [Abstract][Full Text] [Related]
20. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
